Share
EAST LANSING, Mich. — Alerje, a Detroit-based company developing medical devices and software to effectively manage severe food allergies, has secured a follow-on investment from Michigan Rise Pre-Seed Fund III.
Led by founder Javier Evelyn, who has personally experienced the challenges of living with severe allergies, Alerje (pronounced just like “allergy”) is dedicated to enhancing the quality of life for the more than 220 million people affected by life-threatening food allergies. Their main products are a “smart” epinephrine autoinjector and software solutions for allergy clinics that provide oral immunotherapy treatments. The autoinjector is designed to notify caregivers and first responders during a medical emergency and provide vital information about the patient’s medical history, allergies, and location.
“We continue to be impressed by the resourcefulness of the Alerje team since our initial investment in 2021,” said Matt Okoneski, Senior Venture Associate at Michigan Rise. “We’re excited to see their software platform launch later this year, and look forward to product development on their revolutionary epinephrine autoinjector”
The investment from Michigan Rise will help Alerje expand its range of products designed to simplify the management of severe food allergies.
